-
Border casinos caught in Thailand-Cambodia crossfire
-
Australia's Head slams unbeaten 142 to crush England's Ashes hopes
-
Epstein files due as US confronts long-delayed reckoning
-
'Not our enemy': Rush to rearm sparks backlash in east Germany
-
West Indies 110-0, trail by 465, after Conway's epic 227 for New Zealand
-
Arsonists target Bangladesh newspapers after student leader's death
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Tears at tribute to firefighter killed in Hong Kong blaze
-
Seahawks edge Rams in overtime thriller to seize NFC lead
-
Teenager Flagg leads Mavericks to upset of Pistons
-
Australia's Head fires quickfire 68 as England's Ashes hopes fade
-
Conway falls for 227 as New Zealand declare at 575-8 in West Indies Test
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
Conway falls for 227 as New Zealand pass 500 in West Indies Test
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Giant lanterns light up Christmas in Catholic Philippines
-
TikTok: key things to know
-
Putin, emboldened by Ukraine gains, to hold annual presser
-
Deportation fears spur US migrants to entrust guardianship of their children
-
Upstart gangsters shake Japan's yakuza
-
Trump signs $900 bn defense policy bill into law
-
Stokes's 83 gives England hope as Australia lead by 102 in 3rd Test
-
Go long: the rise and rise of the NFL field goal
-
Australia announces gun buyback, day of 'reflection' after Bondi shooting
-
New Zealand Cricket chief quits after split over new T20 league
-
England all out for 286, trail Australia by 85 in 3rd Test
-
Australian announces gun buyback, day of 'reflection' after Bondi shooting
-
Joshua takes huge weight advantage into Paul fight
-
TikTok signs joint venture deal to end US ban threat
-
Conway's glorious 200 powers New Zealand to 424-3 against West Indies
-
WNBA lockout looms closer after player vote authorizes strike
-
Honduras begins partial vote recount in Trump-dominated election
-
Nike shares slump as China struggles continue
-
Hundreds swim, float at Bondi Beach to honour shooting victims
-
Crunch time for EU leaders on tapping Russian assets for Ukraine
-
Pope replaces New York's pro-Trump Cardinal with pro-migrant Chicagoan
-
Trump orders marijuana reclassified as less dangerous drug
-
Rams ace Nacua apologizes over 'antisemitic' gesture furor
-
McIlroy wins BBC sports personality award for 2025 heroics
-
Napoli beat Milan in Italian Super Cup semi-final
-
Violence erupts in Bangladesh after wounded youth leader dies
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
US hosting new Gaza talks to push next phase of deal
-
Chicago Bears mulling Indiana home over public funding standoff
-
Trump renames Kennedy arts center after himself
-
Trump rebrands housing supplement as $1,776 bonuses for US troops
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
D.Schneider--BTB